This clinical data is consistent with our in vitro data identifying a co-operation between N-cadherin and ARF3, wherein ARF3 and N-cadherin mutually control each other’s levels and function in tumorigenesis, with reduced N-cadherin protein associated with metastatic, recurrent prostate cancer. The gene discussed is ARF3; the disease is prostate carcinoma.